Literature DB >> 11296130

The biology of acute promyelocytic leukemia.

K K Mann1, W Shao, W H Miller.   

Abstract

Acute promyelocytic leukemia (APL) is a disease associated with fusion oncoproteins invariably involving the retinoic acid receptor (Raralpha). Retinoic acid induces differentiation in APL cells and is successfully used in conjunction with chemotherapy to treat and cure a significant percentage of patients with APL. APL is also a model for disruption of normal retinoid-mediated transcription resulting in blocked differentiation. The study of the molecular mechanisms of APL oncogenesis has revealed novel interactions between fusion oncoproteins and transcriptional coregulators, already leading to new treatment strategies.

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11296130     DOI： 10.1007/s11912-001-0052-1

Source DB:  PubMed          Journal:  Curr Oncol Rep        ISSN： 1523-3790            Impact factor:   5.945


  70 in total

Review 1.  In vivo analysis of the molecular pathogenesis of acute promyelocytic leukemia in the mouse and its therapeutic implications.

Authors:  L Z He; T Merghoub; P P Pandolfi
Journal:  Oncogene       Date:  1999-09-20       Impact factor: 9.867

2.  A complex containing N-CoR, mSin3 and histone deacetylase mediates transcriptional repression.

Authors:  T Heinzel; R M Lavinsky; T M Mullen; M Söderstrom; C D Laherty; J Torchia; W M Yang; G Brard; S D Ngo; J R Davie; E Seto; R N Eisenman; D W Rose; C K Glass; M G Rosenfeld
Journal:  Nature       Date:  1997-05-01       Impact factor: 49.962

3.  All-trans retinoic acid as a differentiation therapy for acute promyelocytic leukemia. I. Clinical results.

Authors:  S Castaigne; C Chomienne; M T Daniel; P Ballerini; R Berger; P Fenaux; L Degos
Journal:  Blood       Date:  1990-11-01       Impact factor: 22.113

4.  Acute leukemia with promyelocytic features in PML/RARalpha transgenic mice.

Authors:  L Z He; C Tribioli; R Rivi; D Peruzzi; P G Pelicci; V Soares; G Cattoretti; P P Pandolfi
Journal:  Proc Natl Acad Sci U S A       Date:  1997-05-13       Impact factor: 11.205

5.  15/17 translocation, a consistent chromosomal change in acute promyelocytic leukaemia.

Authors:  J D Rowley; H M Golomb; C Dougherty
Journal:  Lancet       Date:  1977-03-05       Impact factor: 79.321

6.  Arsenic trioxide selectively induces acute promyelocytic leukemia cell apoptosis via a hydrogen peroxide-dependent pathway.

Authors:  Y Jing; J Dai; R M Chalmers-Redman; W G Tatton; S Waxman
Journal:  Blood       Date:  1999-09-15       Impact factor: 22.113

7.  Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia.

Authors:  M E Huang; Y C Ye; S R Chen; J R Chai; J X Lu; L Zhoa; L J Gu; Z Y Wang
Journal:  Blood       Date:  1988-08       Impact factor: 22.113

8.  PML, a growth suppressor disrupted in acute promyelocytic leukemia.

Authors:  Z M Mu; K V Chin; J H Liu; G Lozano; K S Chang
Journal:  Mol Cell Biol       Date:  1994-10       Impact factor: 4.272

9.  Molecular analysis of acute promyelocytic leukemia breakpoint cluster region on chromosome 17.

Authors:  J Borrow; A D Goddard; D Sheer; E Solomon
Journal:  Science       Date:  1990-09-28       Impact factor: 47.728

10.  The solution structure of the RING finger domain from the acute promyelocytic leukaemia proto-oncoprotein PML.

Authors:  K L Borden; M N Boddy; J Lally; N J O'Reilly; S Martin; K Howe; E Solomon; P S Freemont
Journal:  EMBO J       Date:  1995-04-03       Impact factor: 11.598
View more
  2 in total

1.  Physical and functional interaction between PML and TBX2 in the establishment of cellular senescence.

Authors:  Nadine Martin; Moussa Benhamed; Karim Nacerddine; Maud D Demarque; Maarten van Lohuizen; Anne Dejean; Oliver Bischof
Journal:  EMBO J       Date:  2011-10-14       Impact factor: 11.598

2.  RNAi screen identifies UBE2D3 as a mediator of all-trans retinoic acid-induced cell growth arrest in human acute promyelocytic NB4 cells.

Authors:  Hidenori Hattori; Xueqing Zhang; Yonghui Jia; Kulandayan K Subramanian; Hakryul Jo; Fabien Loison; Peter E Newburger; Hongbo R Luo
Journal:  Blood       Date:  2007-04-09       Impact factor: 22.113
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.